Growth Hormone Secretagogues

Sermorelin

Also known as Sermorelin acetate · GRF 1-29 · GHRH(1-29) · Geref

Emerging researchSubcutaneous injectionPreviously FDA-approved (1990s); the branded product was discontinued in 2006 for commercial reasons and is no longer marketed as an FDA-approved finished drug. In the US it is encountered as a compounded prescription preparation. Prohibited in sport (WADA, S2).

Sermorelin is a synthetic analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH), the bioactive fragment of the natural hormone. It binds GHRH receptors on pituitary somatotrophs to stimulate the body's own pulsatile release of growth hormone rather than supplying growth hormone directly. It was originally an FDA-approved drug used in pediatric growth hormone-deficiency treatment and diagnostic testing before the manufacturer discontinued the branded product in 2006 for commercial reasons.

Studied / used for

Historically used in protocols for diagnostic evaluation of growth hormone secretion
Historically used in protocols for pediatric growth hormone deficiency
Studied in the context of age-related decline in growth hormone

Commonly reported side effects

Injection-site redness, swelling, or pain
Flushing
Headache
Fluid retention or mild edema
Dizziness

Emerging research. Active research; human evidence still developing. This reflects the strength of the research base, not effectiveness or a recommendation.

Not medical advice.

This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.

← Back to all compounds